Citigroup Inc Cor Medix Inc. Call Options Transaction History
Citigroup Inc
- $217 Billion
- Q3 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding CRMD
# of Institutions
201Shares Held
36.2MCall Options Held
1.34MPut Options Held
1.26M-
Vanguard Group Inc Valley Forge, PA3.98MShares$45.1 Million0.0% of portfolio
-
Black Rock Inc. New York, NY3.55MShares$40.3 Million0.0% of portfolio
-
Marshall Wace, LLP London, X03.47MShares$39.4 Million0.05% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.32MShares$37.7 Million0.74% of portfolio
-
State Street Corp Boston, MA1.84MShares$20.8 Million0.0% of portfolio
About CorMedix Inc.
- Ticker CRMD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 41,208,200
- Market Cap $467M
- Description
- CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of cathet...